Lacosamide Anfarm (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises the inactive state of the channels, reducing repetitive neuronal firing and decreasing neuronal hyper‑excitability that contributes to seizure generation.

The appropriate dose of Lacosamide Anfarm is determined by the prescribing clinician based on the individual patient's clinical condition, response to therapy, and any relevant renal or hepatic considerations. No fixed dosing regimen is provided here; dosing must follow the prescriber’s instructions.

Safety data for Lacosamide in pregnancy and lactation are limited. The drug is classified as having an unknown pregnancy category, so clinicians must weigh the potential benefits against possible risks and consider alternative treatments when appropriate.

To order Lacosamide Anfarm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Lacosamide belongs to the sodium channel blocker class but differs from older agents such as carbamazepine or phenytoin by selectively enhancing slow inactivation rather than fast inactivation. This distinct mechanism may offer improved tolerability and efficacy in patients who have not responded adequately to traditional sodium‑channel blockers.

Lacosamide Anfarm should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Keep the product in its original packaging until use to maintain stability and potency.

Lacosamide Anfarm is supplied as a sterile solution for injection and is administered intravenously. It is typically given as a slow infusion over several minutes under medical supervision, following the dosing instructions provided by the treating physician.

Serious risks include cardiac arrhythmias such as atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, and hypersensitivity reactions that can lead to anaphylaxis. Patients should be monitored for these events, especially during the initiation of therapy or when dose adjustments are made.

Lacosamide Anfarm should be avoided in patients with known hypersensitivity to lacosamide or any component of the formulation, and in those with severe cardiac conduction disorders (e.g., advanced atrioventricular block) unless close cardiac monitoring is possible. Caution is also advised for patients with significant renal or hepatic impairment.